From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
Trade names Atelec (アテレック), Cilacar
AHFS/ International Drug Names
ATC code
CAS Number
PubChem CID
ECHA InfoCard 100.162.338
Chemical and physical data
Formula C27H28N2O7
Molar mass 492.52 g/mol
3D model (Jmol)

Cilnidipine (INN) is a calcium channel blocker, it is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. It was jointly developed by Fuji Viscera Pharmaceutical Company and Ajinomoto, which are based in Japan, and was approved to come into market for the first time and used as anti-hypertensive in 1995. Unlike other calcium antagonists, Cilnidipine can act on the N-type calcium channel in addition to acting on L-type calcium channel like most other calcium antagonists. Cilnidipine is approved for use in Japan, China, India, Korea, and some European countries. Hypertension is the most common cardiovascular disease. Around 50 million individuals in the United States and 1 billion individuals worldwide are affected by hypertension

Medical uses[edit]

Cilnidipine is used to manage hypertension. Due to its blocking action at N-type and L type calcium channel, cilnidipine dilates both arterioles and venules, reducing the pressure in the capillary bed.

Adverse effects[edit]

Peripheral edema, a common side effect of the use of amlodipine, was reduced when patients were shifted to cilnidipine (citation needed).

Clinical Benefits[edit]

Cilnidipine has enhanced lipophilicity, leading to prolonged anti-hypertensive effects, correlated with occupancy of the binding site. In 24-hour clinical assessment, once-daily administration of cilnidipine reduced blood pressure (citation needed). The inhibitory effect on the N-type Ca2+ channel may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia (citation needed).

As catecholamines induce platelet activation via α2-receptor on the platelet membrane, a decrease in nor-epinephrine levels by cilnidipine causes attenuation of platelet activation.

Brand names[edit]

In Bangladesh it is marketed by The Acme Laboratories Ltd. under the brand name Duocard, available as both 5 mg & 10 mg and Opsonin Pharma Ltd. In India it is marketed by JBCPL under the brand name "Cilacar" and is available in 5 mg, 10 mg, 20 mg and other combinations. In Japan it is marketed by Ajinomoto Pharmaceuticals Co., Ltd.under the brand name "Atelec". In the United States it is available through different brands, including "Atelec" and "Cilacar."


External links[edit]

  • Löhn M, Muzzulini U, Essin K, et al. (May 2002). "Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C". J. Hypertens. 20 (5): 885–93. doi:10.1097/00004872-200205000-00023. PMID 12011649. 
  • 1. Cardiovascular Therapeutics 27 (2009) 2. Cardiovascular Drugs and Therapy 1997 3. Can J Anesth. 2002. 4. Clinical and Experimental Hypertension,2009. 5. J Clin Hypertens (Greenwich). 2013 6. Hypertens Res 2003; 7. Journal of Diabetes Investigation; 2012.8 .Journal of Cardiology (2009) . 9 J Cardiovasc Pharmacol; 2007 10.J Cardiovasc Pharmacol 2004, 11 Antihypertensive Drug 2012, 12 J Hypertens. 2010 May. 13 J Hypertens. 2010 14 Hypertens Res. 2012 15 Diabetes Res Clin Pract. 2012 16 Neurochem Int. 2012, 17 J. Neurochem. (2009) 18 Geriatr Gerontol Int 2008; , 19 Biol. Pharm. Bull. (2004), 20 Clin Calcium. 2010 20.